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Abstract
Background: sarcopenia registries are a potential method to meet the challenge of recruitment to sarcopenia trials. We tested
the feasibility of setting up a UK sarcopenia registry, the feasibility of recruitment methods and sought to characterise the
pilot registry population.
Methods: six diverse UK sites took part, with potential participants aged 65 and over approached via mailshots from local
primary care practices. Telephone pre-screening using the SARC-F score was followed by in-person screening and baseline visit.
Co-morbidities, medications, grip strength, Short Physical Performance Battery, bioimpedance analysis, Geriatric Depression
Score, Montreal Cognitive Assessment, Sarcopenia Quality of Life score were performed and permission sought for future
recontact. Descriptive statistics for recruitment rates and baseline measures were generated; an embedded randomised trial
examined the effect of a University logo on the primary care mailshot on recruitment rates.
Results: sixteen practices contributed a total of 3,508 letters. In total, 428 replies were received (12% response rate); 380
underwent telephone pre-screening of whom 215 (57%) were eligible to attend a screening visit; 150 participants were
recruited (40% of those pre-screened) with 147 contributing baseline data. No significant difference was seen in response
rates between mailshots with and without the logo (between-group difference 1.1% [95% confidence interval −1.0% to
3.4%], P = 0.31). The mean age of enrollees was 78 years; 72 (49%) were women. In total, 138/147 (94%) had probable
sarcopenia on European Working Group on Sarcopenia 2019 criteria and 145/147 (98%) agreed to be recontacted about
future studies.
Conclusion: recruitment to a multisite UK sarcopenia registry is feasible, with high levels of consent for recontact.
Keywords: sarcopenia, older people, recruitment, registry
Key Points
• Recruiting to sarcopenia studies is challenging; registries have proved to be useful for other underserved patient groups.
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• Over 90% of registrants fulfilled the EWGSOP 2019 criteria for probable sarcopenia.
• In total, 98% of participants agreed to be recontacted for future clinical studies.
Introduction
Sarcopenia, the loss of muscle strength and mass [1], is
an important health problem for many older people. It
is a major underlying cause of falls, impairment in activ-
ities of daily living and the need for care and is a sig-
nificant contributor to hospitalisation, increased length of
stay and earlier death [2, 3]. Resistance training is the
only intervention with good evidence for the treatment
of sarcopenia [4], but not all older people are able to or
willing to undertake resistance training. Our understanding
of the pathophysiology of sarcopenia is advancing rapidly,
with multiple lines of therapeutic enquiry [5], and there
is therefore a pressing need to conduct clinical trials to
test potential interventions to prevent and treat sarcopenia
[6].
Undertaking clinical trials for sarcopenia presents mul-
tiple challenges. The diagnosis is not commonly made in
clinical practice in part due to the need to measure muscle
mass and muscle strength [7, 8]. Many clinical sites do not
have easy access to equipment (for instance bioimpedance or
whole-body dual-energy X-ray absorptiometry) within the
clinical environment to enable the diagnosis to be made.
Even when the diagnosis is made it is often not system-
atically recorded in searchable electronic health records or
databases. Finding participants with sarcopenia for clinical
trials is therefore challenging and often requires screening
large numbers of potential participants in order to identify
those with sarcopenia. Previous trials have found recruitment
of patients with sarcopenia to be difficult and have often
either used a more relaxed definition of sarcopenia than that
stipulated in current guidelines [9, 10] or have failed to
reach their recruitment targets [11]. While many hospital
inpatients have sarcopenia, many are too unwell or too frail
to take part in trials.
Disease registries provide one solution to this challenge.
Registries have been used successfully in other long-term
conditions such as bronchiectasis and rare neuromuscular
conditions [12, 13]. They allow a pool of eligible participants
to be recruited and identified over an extended period across
multiple sites even when a trial is not active. Signing up
to a registry can include consent to recontact participants
when a suitable trial becomes available. Because participants
are pre-screened with phenotypic data already collected, the
process of selecting participants for a given clinical trial can
be much more rapid and efficient. Although plans have
been established for a sarcopenia registry in Europe [14], no
registry currently exists in the United Kingdom. The aim of
this project was therefore to test recruitment processes for a
UK sarcopenia registry and to characterise those willing to
participate in such a registry.
Methods
Study population
The SarcNet registry pilot study was designed as an obser-
vational study with longitudinal follow-up. The target pop-
ulation was people aged 65 and over with self-reported
impairment in physical function. The study Sponsor was
Newcastle University, and the study was approved by the
North East—Tyne and Wear South NHS Research Ethics
Committee (reference 18/NE/0314). Written informed con-
sent was obtained from all participants.
Recruitment strategy
Six hospital sites were selected to give geographical and
demographic contrast in coverage. Sites were selected to
cover major cities versus smaller population centres, areas
with high versus low ethnic diversity and north versus
south of England. Participants were recruited from primary
care organisations (General Practices) located near to each
recruiting centre. Primary care practices willing to take part
screened their practice lists to identify potentially eligible
participants aged 65 and over, supported by the National
Institute for Healthcare Research Primary Care Research
Network. A clinical member of staff at the primary care
practice then screened the generated lists to remove the
name of any individual who they deemed it inappropriate
to approach; criteria suggested by the study team for this
were patients approaching the end of life and those who
had previously stated a wish not to engage with research.
Invitations were mailed to potential participants on behalf
of participating primary care practices using the DocMail
mailshot system (CFH Docmail, Radstock UK). DocMail
allows documents to be uploaded by the research team
to a secure website, combined with names and addresses
uploaded by primary care practices, with automated
printing, packaging and postage of the information packs
to recipients. Reply slips were returned via a business reply
mail service to the central research team in Newcastle.
Screening and eligibility
Positive responses were sent to the relevant local research
team, who then contacted participants via telephone. At this
initial telephone pre-screening call, a brief series of questions
including date of birth, the presence of a pacemaker or
defibrillator (a contraindication to bioimpedance measure-
ment) and the five-question SARC-F sarcopenia screening
score [15] were asked to assess eligibility. Participants had to
score 3 or more (out of 10) on the SARC-F questionnaire
at pre-screening; this threshold was selected to ensure
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functional impairment. Eligible participants who still
expressed interest were then sent the full-study information
sheet by the research team and were invited to a combined
in-person screening/baseline visit. This took place in a
secondary care clinic, research facility or, if the participant
chose, in their own home. Exclusion criteria assessed at
the screening visit were life expectancy of <6 months in
the judgement of the local investigator, participation in an
interventional study within the last 30 days, presence of a
permanent pacemaker with an atrial sensing lead or presence
of an implantable cardioverter–defibrillator (both con-
traindications to bioimpedance testing), peripheral oedema
present above knee level or body temperature >38◦C at the
baseline visit (both likely to affect bioimpedance accuracy).
Measures collected
Hand grip strength was measured using a Jamar hydraulic
dynamometer (Lafayette Instrument Company, USA); three
measurements were recorded on each hand and the maxi-
mum used for analysis [16]. Appendicular lean muscle mass
was assessed using the Akern 101 bioimpedance system
(Akern SRL, Pontassieve, Italy); the Sergi equation was used
to derive appendicular lean mass [17]. The Short Physical
Performance Battery (SPPB) was conducted, comprising
tandem and semi-tandem balance, five times sit to stand
and gait speed measured over a 4-m course [18]. Rea-
sons for not completing physical performance measures and
bioimpedance were collected (unable, declined or technical
problem). The Sarcopenia Quality of Life (SarQoL) ques-
tionnaire was administered to assess quality of life [19]. Cog-
nition was assessed using the Montreal Cognitive Assessment
(MoCA) [20] and depressive symptoms using the 15-point
geriatric depression score [21]. Height, weight, medication
use, medical history and the most recent blood results from
routine clinical practice in the last 12 months were recorded.
Embedded trial of intervention to boost mailshot
response rate
As part of SarcNet, we conducted an embedded randomised
controlled trial of a simple intervention that aimed to boost
mailshot response rates. Although mailshots provide a cost-
effective way to reach large numbers of potentially eligi-
ble participants, response rates are often low, with many
recipients not even opening the letter. Previous studies have
tested whether envelope colour or inclusion of a pen increases
response rates to trial invitations, but the effect of including
the logo of a trusted provider (e.g. a primary care practice,
hospital or University) on the mailshot envelope (to signal
that the envelope is unlikely to be junk mail) has not
previously been tested in a randomised trial [22, 23]. The
intervention we chose was the addition of the Newcastle
University logo (as study Sponsor) to the outside envelope
containing study information that was mailed to potential
participants. The control arm received the same envelope but
without any logo on the front. The internal content of all
envelopes was identical. Randomisation was performed at
the level of individual mail shots (i.e. all letters in a single
mailshot either had or did not have the logo added) and was
stratified by centre and by primary care practice. Randomi-
sation codes were generated by an individual not otherwise
associated with the trial; participants and investigators were,
however, not blinded to intervention allocation.
Statistical analysis
All statistical analyses were conducted using SPSS v24 (IBM,
New York). A two-sided P-value of <0.05 was taken as
significant for all analyses. Descriptive statistics were gener-
ated for baseline characteristics of the enrolled population,
along with descriptive characteristics for each stage of the
recruitment process. For the embedded randomised con-
trolled trial, the primary outcome (the proportion of letters
generating a positive reply [mail slip or telephone contact]
was compared using Pearson’s chi-squared test with 95%
confidence intervals (CIs). Baseline measures of physical
performance were correlated with baseline age, quality of life,
selected blood test results, medication number and number
of conditions, SARC-F score and muscle mass. Pearson’s
correlations were used where both variables were normally
distributed; Spearman’s correlation was used where one or
both variables were not normally distributed.
Results
Recruitment strategy
Six recruitment sites were activated during the pilot
project—Gateshead, Lewisham, Exeter, Bradford, Leeds and
Solent. In total, 20 mailshots were sent out from 16 primary
care practices; the size of mailshot varied from 35 to 313. A
total of 3,508 letters were mailed out. In total, 428 replies
were received (12% response rate); 380 underwent telephone
prescreening of whom 215 (57%) were eligible to attend a
screening visit; 150 participants were recruited (40% of those
undergoing telephone prescreen). Details of response rates,
telephone pre-screening pass rates and enrolment rates at
each of the six sites are given in Table 1. Recruitment took
place between July 2019 and March 2020, when activity was
stopped due to restrictions on research activity imposed as
part of the COVID-19 pandemic response in the United
Kingdom. To minimise practice workload and to preserve
confidentiality, practices did not collect, share or report
information on the age or sex of patients included in the
mailshots.
Embedded trial
The CONsolidated Standards Of Reporting Trials (CON-
SORT) diagram for the embedded randomised controlled
trial of using the Newcastle University logo on the mail-
shot envelope is shown in Figure 1. No significant differ-
ence was seen in positive response rates between mailshots







/ageing/advance-article/doi/10.1093/ageing/afab084/6284387 by Edinburgh U
niversity user on 09 June 2021
M. D. Witham et al.









Leeds (3 practices) Solent (3 practices) Total
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Letters sent 526 48 700 859 560 815 3,508
Positive responses (%
of total letters sent)
93 (17.7) 11 (22.9) 153 (21.9) 39 (4.5) 50 (8.9) 82 (10.1) 428 (12.2)
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2 unable to communicate
by phone; 2 declined
prior to phone screen; 1
due to COVID)
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Eligible to progress to



































22 (30.1) (5 unable to
progress due to COVID;
7 declined due to illness)
150 (39.5)
logo (248/2109 [11.8%]). The between group difference in
response rates was 1.1% (95%CI −1.0 to 3.4%, P = 0.31).
Baseline data
Three participants of the 150 enrolled did not complete base-
line assessment; two due to illness and one due to the onset of
the COVID-19 pandemic stopping non-COVID research.
Baseline details for the population contributing baseline data
(n = 147) are given in Table 2. In total, 73 (49%) elected to
have the baseline visit conducted in their own home. The
majority of participants had significantly impaired physical
function, with low walk speed, low SPPB scores, impaired
sit to stand scores and weak grip strength. The proportion of
participants with low muscle mass according to the European
Working Group on Sarcopenia in Older People (EWGSOP)
2019 cut-offs differed greatly depending on body mass index
(BMI); for those with BMI <18.5 kg/m2, 1 of 1 (100%) had
low muscle mass; 16/23 (70%) of those with BMI 18.5–
24.9 kg/m2 had low muscle mass, as did 15/52 (29%) of
those with BMI 25.0–29.9 kg/m2. The largest group was of
those with BMI >30 kg/m2), of whom 0/71 (0%) had a low
muscle mass.
Proportion with sarcopenia in the enrolled
population
The proportions of enrolled individuals meeting the criteria
for sarcopenia, probable sarcopenia under a series of different
definitions, and different physical performance cutoffs are
shown in Table 3. EWGSOP 2019 guidelines suggest a
diagnosis of ‘probable sarcopenia’ can be made according
to muscle strength cut-offs (low grip strength or prolonged
chair stand time). Using this definition, 94% of enrolled
participants had a diagnosis of probable sarcopenia. For a
diagnosis of ‘confirmed’ sarcopenia, demonstration of low
muscle mass is also required. Consistent with the proportions
of participants with low muscle mass reported above, fewer
than a fifth of participants met the criteria for ‘definite’
sarcopenia.
Relationship of baseline physical performance to
other baseline measures
The SARC-F score showed a moderate correlation with grip
strength, walk speed and the SPPB score as shown in Table 4.
The relationship between physical function and sarcopenia-
specific quality of life was weak but reached significance
for male grip strength and the SPPB score. Baseline bio-
chemical and haematological indices were not significantly
associated with baseline physical performance, but higher
burden of multimorbidity was associated with lower physical
performance.
Proportion agreeing to enter registry
In total, 145/147 (98%) of participants completing the
baseline assessment consented to be held on the registry to
be contactable for future studies. Of these, 125 (85%) were
happy to be contacted by letter, 21 (14%) by email, 59 (40%)
by telephone and 10 (7%) by text messaging.
Discussion
We describe the first sarcopenia registry to be set up in the
United Kingdom and show that such a registry is feasible
and acceptable to participants who enrolled. Rates of consent
for recontacting for future studies were very high suggesting
that such a registry can perform its primary purpose of
providing a pool of participants who are phenotyped and
contactable for future clinical trial enrolment. Although
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Figure 1. CONSORT flow diagram for recruitment into embedded trial.
our recruitment strategy succeeded in enrolling a high pro-
portion of participants with probable sarcopenia accord-
ing to EWGSOP 2019 guidelines. Confirmed sarcopenia
including low muscle mass as a criterion was, however, less
common, in line with previous population-based cohort
studies [24].
Our recruitment strategy using primary care mailshots
was successful, and we were able to reach large numbers
of potential participants with relatively low cost and effort
despite the relatively low response rate. The use of telephone
prescreening reduced the number of face-to-face visits that
participants needed to attend with a consequent reduction in
study burden, and this also contributed to low failure rates at
the face-to-face screening visits. Such an approach increases
the efficiency of recruitment process. The choice of visits at
home rather than at a study centre was popular, with half of
participants taking up this option; this flexibility may have
encouraged some people to take part who otherwise would
have declined. Although we used the SARC-F questionnaire
with a cut-off of 3 or more to ensure that all participants
had a degree of impairment of daily activities, it may be
possible to use a lower cut-off than we used in this study;
recent population studies have suggested that a score of
one or above might be equally effective in identifying those
with sarcopenia [25]. Despite the success of the recruitment
strategy in the current study, other strategies for additional
potential registry recruitment could include direct response
to adverts by potential participants, recruitment from sec-
ondary care clinics including geriatric medicine clinics or
opt-out recruitment strategies [26].
We noted considerable variability between sites in their
ability to engage local primary care practices to help with
recruitment as well as in response rates from mailshots.
We deliberately chose a range of sites including urban and
rural sites, sites in affluent and deprived areas, sites with
predominantly white populations and sites serving popula-
tions with a high proportion of people from ethnic minor-
ity communities. It was noteworthy that sites with a high
proportion of people from ethnic minority communities
had a low response rate to mailshots, although we were not
able to break down the individual response rate or final
recruitment numbers by ethnicity in this study. Our findings
highlight the fact that more tailored approaches are necessary
to effectively reach members of ethnic minority communi-
ties. We did not provide translations of information sheets
in this pilot study, although recruitment staff belonging to
local ethnic minority communities were used in two of the
sites [27], and this may have helped to improve rates of
progression from pre-screening through to enrolment. Even
when translated written materials are available, alternatives
to written information may be more effective for some
groups [28]. We did not collect data on deprivation or
other lifestyle factors such as diet and activity in order to
keep the amount of data collected to a manageable level.
The registry, however, provides an ideal platform for more
detailed enquiry into the relationship between these factors
and sarcopenia in future studies.
Our embedded randomised controlled trial of the inclu-
sion of the Newcastle University logo on the mailshot enve-
lope did not show a significant effect on return rates for
expressions of interest. Our hypothesis that a University logo
would differentiate the mailshot from junk mail (i.e. it would
act as a badge of trust) did not translate into a meaningful
difference in return rates. This may be because the logo was
not viewed as a badge of trust by potential participants,
or it may be that potential participants opened all of their
mail regardless of whether they thought it was junk and
that the presence of a logo did not influence the decision to
open the envelope. No previous randomised controlled trials
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Table 2. Details for participants undergoing baseline assessment (n = 147)
Mean age (years) (SD) 77.6 (7.3)
Female sex (%) 72 (49)
Max handgrip strength (kg) (SD) Men 27.2 (9.4)
Women 15.7 (6.1)
Mean BMI (kg/m2) (SD) 30.2 (6.2)
Mean BIA muscle massa (kg/m2) (SD) Men (n = 70) 7.84 (1.21)
Women (n = 69) 6.65 (1.13)
Mean SPPB (SD) 5.5 (2.3)
Mean walk speed (m/s) (SD) n = 142b 0.61 (0.24)
Median chair stand time (s) (IQR) n = 106c 24.0 (17.4–32.0)
Mean SARC-F score (SD) 5.3 (1.8)
Conditions (%) Ischaemic heart disease 40 (27)
Stroke 25 (17)
Chronic heart failure 17 (11)
Diabetes mellitus 35 (24)
Atrial fibrillation 25 (17)




Parkinsonian syndromes 3 (2)
Chronic obstructive pulmonary disease 24 (16)
Asthma 25 (17)
Other lung disease 22 (15)
Osteoarthritis 66 (45)
Inflammatory arthropathy 8 (5)
Proportion with multimorbidity (2 or more long-term conditions) (%) 100 (68)
Median (IQR) number of medications 8 (6–11)
Fried frailty category (%) Non-frail 27 (18)
Pre-frail 94 (64)
Frail 26 (18)
Median MoCA score (IQR) n = 133 23 (20.5–26)
Geriatric Depression Score (SD) 4.2 (3.2)
SarQoL score (SD) (best = 100) 51 (12)
Haemoglobin (g/l) (SD) n = 122 133 (13)
eGFR (ml/min/1.73 m2) (SD) n = 131 68 (18)
Albumin (g/l) n = 106 41 (4)
BIA, bioimpedance assessment; eGFR: estimated glomerular filtration rate; IQR, interquartile range; SD, standard deviation. aAppendicular skeletal muscle mass
index by Sergi equation bReasons for non-completion: wheelchair use (n = 1); no reason given (n = 4) cUnable to complete five stands (n = 39); unable to stand
without human assistance (n = 2)
















. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Men 13 (17%) 33 (44%) 56 (75%) 67 (89%) 71 (95%) 18 (24%) 11 (15%) 15 (20%)
Women 8 (11%) 35 (49%) 60 (83%) 65 (90%) 67 (93%) 9 (13%) 7 (10%) 14 (19%)
All 21 (14%) 68 (46%) 116 (79%) 132 (90%) 138 (94%) 27 (18%) 18 (12%) 29 (20%)
FNIH, Foundation for the National Institutes of Health. aLow grip strength (<30 kg men or <20 kg women) OR walk speed ≤0.8 m/s AND low appendicular
muscle mass index (<7.26 kg/m2 men or < 5.5 kg/m2 women) bLow grip strength (<27 kg men or <16 kg women) cLow grip strength (<27 kg men or <16 kg
women) OR sit to stand test >15 s/unable to complete dLow grip strength (<27 kg men or <16 kg women) OR sit to stand test >15 s/unable to complete, AND
low appendicular muscle mass index (<7.0 kg/m2 men or <5.5 kg/m2 women) eAs for (c) but with walk speed ≤0.8 m/s fLow grip strength (<26 kg men or <16 kg
women) AND low appendicular lean mass (lean mass in kg divided by BMI in kg/m2 <0.789 for men or <0.512 for women)
findings, however, add to the growing body of evidence from
other studies within a trial of what interventions are effective
at improving recruitment rates to clinical research studies
[22]. Further studies could usefully examine whether logos
from healthcare providers, or local rather than remote aca-
demic institutions, might be more effective at encouraging
recruitment.
For sarcopenia trials to be representative of the population
seen in clinical practice, the trial population needs not only
to fulfil the criteria for sarcopenia but also needs to reflect
the age and capability of people seen in clinical practice. Our
registry population has high levels of co-morbid disease with
over two-thirds of participants having multimorbidity; the
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Table 4. Association between baseline measures of muscle function and selected baseline variables (n = 147)
Walk speed SPPB Grip strength (men) Grip strength (women)
r P r P r P r P
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age -0.11 0.21 -0.12 0.16 -0.17 0.14 0.02 0.89
SARC-F −0.33 <0.001 −0.40 <0.001 −0.41 <0.001 −0.25 0.02
SarQoL 0.15 0.08 0.23 0.006 0.35 0.002 0.23 0.09
Haemoglobin 0.04 0.67 0.09 0.33 0.20 0.11 0.07 0.62
Albumin 0.86 0.38 0.03 0.73 0.19 0.14 0.01 0.94
eGFR 0.92 0.31 0.14 0.12 0.03 0.79 -0.25 0.05
Appendicular
muscle mass
-0.94 0.31 -0.05 0.54 0.13 0.30 0.26 0.03
Number of
conditions∗
−0.20 0.02 −0.19 0.03 -0.08 0.51 −0.27 0.02
Number of
medications∗
−0.29 <0.001 −0.17 0.04 -0.04 0.74 -0.19 0.10
Pearson’s correlation coefficient except for ∗Spearman’s rho. The bold results are where p<0.05.
performance measures are reflective of the population of
older people seen in primary care and in geriatric medicine
practice in secondary care. Although sarcopenia is relatively
common in selected populations such as those in care homes
and those admitted to hospital, recruitment of these popula-
tions for trials is extremely difficult as this group of patients
are often very unwell, have severe cognitive impairment,
or have very limited life expectancy. In the current study,
participants at some centres were offered the option of having
their screening/baseline visit at home but not all centres were
able to offer this as an option. It is quite possible that the
logistics of attending a clinical research facility was a factor
in actual recruitment rates after telephone screening, and
hence, additional recruitment methods such as recruiting
during other interactions (for example at clinical appoint-
ments or at community visits) may also be important for a
more inclusive registry.
Sarcopenia is considerably less common in the general
population at between 5 and 10% [29], and our find-
ings reinforce that identifying participants with sarcope-
nia remains challenging, in part because muscle mass and
strength are not measured as part of routine clinical prac-
tice in either primary or secondary care in most healthcare
systems. Our findings also reinforce that current defini-
tions of sarcopenia [8] may not make sufficient allowance
for obesity—absolute muscle mass is often preserved in
people with obesity (and patients do not therefore meet
the muscle mass criteria for sarcopenia), but muscle mass
relative to body size is low with consequent impairment of
function.
To be of most use to academic and commercial part-
ners seeking to conduct clinical trials and other studies,
registries need to be of sufficient size and to have a pres-
ence in multiple recruiting centres. Scale up of this UK
sarcopenia registry is therefore a priority and the use of
a large registry would be of great value in enhancing the
UK’s clinical research delivery infrastructure, augmenting
the work of the National Institute for Health Research
(NIHR) Clinical Research Network. Scale up is likely to
require simplification of the data collected, perhaps not only
by linking to routinely collected clinical records but also
by expansion of recruitment streams to incorporate recruit-
ment directly from secondary care clinics (particularly those
already measuring muscle strength and/or muscle mass), via
advertising and via pop-up recruitment clinics in commu-
nity settings. Maintenance of the registry, including replace-
ment of registrants who die, also requires ongoing funding
for recruitment and follow-up. In addition to providing a
way to recruit to future trials, the registry also provides
an opportunity to conduct studies to better understand
sarcopenia and to test and validate new diagnostic tools for
sarcopenia.
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